When Paul Hudson took over as CEO of Sanofi in September 2019, he came in with a bold vision to turn around the struggling French pharma. The plan included going all in on the budding blockbuster Dupixent (dupilumab) and immunology while ending research in the company’s heritage area – diabetes and cardiovascular disease.
Hudson’s vision for the future of Dupixent proved prescient, but the decision to exit metabolic research, including development of a...



